Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs IAC/Interactivecorp (PPLI) Price & Performance

Eli Lilly And CoTrade
IAC/InteractivecorpTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs IAC/Interactivecorp — how do they compare? Eli Lilly And Co trades at $1,206.17 (market cap $1.08T), while IAC/Interactivecorp trades at $40.18 (market cap $2.97B). The key difference: Eli Lilly And Co is far larger — about 363.6× IAC/Interactivecorp's market cap, and Eli Lilly And Co pays a 0.57% dividend while IAC/Interactivecorp pays none. Which is the better fit depends on your goals.

LLYPPLI
Market Cap
$1.08T$2.97B
Sector
HealthMedia
52-Week High
$1.24K$47.62
52-Week Low
$639.43$31.52
Enterprise Value
$1.13T$3.28B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

IAC/Interactivecorp

PPLI trades at $40.66, down 2.21% today, with a bearish technical signal but strong analyst support. Recent Q2 2026 earnings beat expectations with EPS of $6.77, driven by digital growth and MGM investment gains. The company is simplifying its structure and monetizing non-core assets. Valuation ratios appear attractive with a P/E of 6.76 and P/B of 0.59, though revenue has declined from $5.2B in 2022 to $2.4B in 2025.

Outlook is mixed: low valuation and asset monetization offer upside, but declining revenue and volatile earnings pose risks. Analyst consensus is bullish with a $60.50 price target, implying 49% potential upside. Key risks include execution of restructuring and dependence on MGM performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About IAC/Interactivecorp

IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.

Read more on PPLI